Schizophrenia and Bipolar Disorder are two highly prevalent disorders in the US. Diagnosis is limited to observation of clinical symptoms, often leading to under-diagnosis or misdiagnosis. It can therefore take months to years to accurately diagnose an individual and implement an effective treatment. To address this issue, researchers at UCI have identified blood based biomarkers for schizophrenia and bipolar disorder. By determining methods for evaluating expression levels of these biomarkers, they have developed a commercial test to discriminate between normal bipolar disorder and schizophrenia patients, which will allow for more efficient diagnoses. Maria Tkachuk mtkachuk@uci.edu 949-824-2288
Smart, interactive desk
Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the